Current therapeutic strategies for anal squamous cell carcinoma in Japan
- 87 Downloads
In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC). In Japan, the therapeutic modalities for and outcomes of this disease have not been clarified because ASCC is quite rare. The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
In July 2006, a questionnaire was sent to 49 institutions affiliated with the JCOG-CCSG to gather information on numbers of cases, therapeutic modalities, and outcomes. The target subjects were patients with stages II/III ASCC, diagnosed from January 2000 to December 2004, who were 20–80 years of age with normal major organ function and no severe complications.
Replies were received from 40 institutions. A total of 59 patients satisfied the subject criteria. Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC. CRT was performed in 25 patients (45%); surgery in 17 (31%); surgery combined with radiotherapy (RT), chemotherapy, or CRT in 8 (15%); and RT in 5 (9%). Complete response rate in CRT was 80% (20/25). The 3-year progression-free survival rates for all subjects and for CRT-only subjects were 67% and 77%, respectively.
From 2000 to 2004, only 59 patients with ASCC were identified in the JCOG-CCSG survey and about half of them underwent CRT.
Key wordsAnal cancer Squamous cell carcinoma Chemoradiotherapy
- 2.Sameshima S, Sawada T, Nagasako K (2005) Squamous cell carcinoma of anus and carcinoma in association with anal fistula in Japan, multi-institutional registration. J Jpn Soc Coloproctol 58: 415–421Google Scholar
- 8.Leichman L, Nigro N, Vaitkevicius VK, et al. (1985) Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 78:211–215Google Scholar
- 10.Peiffert D, Seitz JF, Rougier P, et al. (1997) Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol 8:575–581CrossRefPubMedGoogle Scholar
- 12.Bartelink H, Roelofsen F, Eschwege F, et al. (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–2049PubMedGoogle Scholar
- 13.UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 19:1049–1054Google Scholar
- 14.Flam M, John M, Pajak TF, et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMedGoogle Scholar